Meeting
2017 ASCO Annual Meeting
Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL).
Authors
Jeffrey S. Weber
Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY
Jeffrey S. Weber , James M. G. Larkin , Dirk Schadendorf , Jedd D. Wolchok , John Wagstaff , Reinhard Dummer , David Hogg , Massimo Guidoboni , Jeffrey Alan Sosman , Bartosz Chmielowski , Winald Gerritsen , Rafia Bhore , Dana Walker , Rene Gonzalez
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT01844505; NCT01927419
Citation
J Clin Oncol 35, 2017 (suppl; abstr 9523)
DOI
10.1200/JCO.2017.35.15_suppl.9523
Abstract #
9523
Poster Bd #
131
Abstract Disclosures
Similar Posters
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy and toxicities of immune checkpoint inhibitors (ICIs) in advanced melanoma: A single institution experience.
First Author: Karim Welaya
Poster
2017 ASCO Annual Meeting
Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).
First Author: David Hogg
Poster
2016 ASCO Annual Meeting
Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069).
First Author: F. Stephen Hodi
Poster
2022 ASCO Annual Meeting
Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.
First Author: F. Stephen Hodi